FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

doi:10.4251/wjgo.v12.i2.182

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12550)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

597

WORD

215

HTML

6828

Figures (1-2)

485

Tables (1-4)

352

Sum=8477

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

586

Download

898

Sum=1484

Publishing Process of This Article

Item

Count

Browse

925

Download

1664

Sum=2589

Feb 15, 2020 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (43)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Feb 15, 2020; 12(2): 182-194
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.182

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall survival and progression-free survival. A: Kaplan-Meier estimates of overall survival; B: Progression-free survival.

Open in New Tab Full Size Figure Download Figure

Figure 2 The treatment efficacy was consistently similar in both groups across the majority of subgroups. A: Forest plots of hazard ratio for overall survival; B: Progression-free survival according to subgroups.

Citation: Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194
URL: https://www.wjgnet.com/1948-5204/full/v12/i2/182.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.182